Tree pollen allergy immunotherapy - Lofarma

Drug Profile

Tree pollen allergy immunotherapy - Lofarma

Alternative Names: LAIS Birch-Alder tablets; Tree-pollen allergoid - Lofarma

Latest Information Update: 04 May 2016

Price : $50

At a glance

  • Originator Lofarma S.p.A
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Allergic rhinoconjunctivitis

Most Recent Events

  • 03 May 2016 No recent reports on development identified - Phase-III for Allergic rhinoconjunctivitis (In the elderly, Prevention, In adults) in Germany (Sublingual)
  • 09 Dec 2013 Phase-III clinical trials in Allergic rhinoconjunctivitis (prevention, in adults and elderly) in Germany (Sublingual) (EudraCT2013-002129-43)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top